To sum up, the role of SREBP1s and SCAP is pivotal in the pathogenesis of MASLD as the former is the main transcription factor involved in lipogenesis activation and the latter is the key mediator in the activation of SREBPs. The gene discussed is SCAP; the disease is metabolic dysfunction-associated steatotic liver disease.